PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
611 episodes - English - Latest episode: 11 days ago - ★★★★★ - 7 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy
July 12, 2021 23:00 - 1 hour VideoGo online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel ther...
Matthew D. Galsky, MD - New and Emerging Therapeutic Strategies in Bladder Cancer: Updates in Early-Stage Disease and Beyond
July 12, 2021 23:00 - 31 minutes VideoGo online to PeerView.com/MHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary oncology discusses new and emerging strategies for the management of patients with bladder cancer. Upon completion of this accredited CE activity, participants should be better able to: Review when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across pati...
Karl D. Lewis, MD - Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
July 08, 2021 23:00 - 1 hour VideoGo online to PeerView.com/TPR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in basal cell carcinoma (BCC) discusses the evidence that supports incorporating immunotherapy into existing treatment protocols for advanced BCC. Scientific lectures are linked with practical, case-centered sessions designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards in order to clearly...
Sara M. Tinsley, PhD, APRN, AOCN - Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learning in Nursing Practice
June 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/EQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS annual meeting, our expert panel discusses tactics on how to maximize clinical outcomes for their lower- and higher-risk patients with myelodysplastic syndromes (MDS), with a focus on current and emerging treatment options. Hear practical insights and real-world case discussions and get informed on key safety and ...
George L. Bakris, MD - Recognizing and Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease: An Update for Hospitalists
June 25, 2021 23:00 - 1 hour VideoGo online to PeerView.com/FNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, leading experts explore the benefits and limitations of newer potassium binders, such as patiromer and sodium zirconium cyclosilicate, and share evidence-based strategies for managing hyperkalemia to improve patient outcomes. Upon completion of this accredited CE activity, participants should be better abl...
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease
June 25, 2021 23:00 - 1 hour VideoGo online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, bu...
Steven W. Pipe, MD - Envisioning the Future of Emerging Nonfactor Therapies in Hemophilia A and B: The Art and Science of RNA Interference
June 25, 2021 23:00 - 24 minutes VideoGo online to PeerView.com/WUP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice. Upon completion of this accredited CE activity, participants should be better able to: Discuss current challenges and new developments in the management of...
Shanu Modi, MD - Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
June 24, 2021 23:00 - 54 minutes VideoGo online to PeerView.com/FXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, medical oncologists discuss the latest advances in managing patients with HER2-positive breast cancer, including an overview of approved and emerging HER2-targeted therapies, and share perspectives on novel targeted therapies and combinations that may improve outcomes in challenging patient subgroups. In addition, practical guidance is offered...
Laura S. Wood, RN, MSN, OCN / Sumanta Kumar Pal, MD - The New Therapeutic Era in Renal Cell Carcinoma: Essentials for Team-Based Patient Care
June 23, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/RYZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Practicum will provide oncology professionals involved in the care of patients with RCC with a strong understanding of how newer therapeutic regimens, such as immune checkpoint inhibitors and new TKIs, fit within the current management paradigm. They will also be offered tools to help them master practical aspects tied to their use...
Ronan J. Kelly, MD, MBA / Siva Raja, MD, PhD, FACS - Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer: The Latest Evidence and Implications for Thoracic Surgeons and the Multidisciplinary Care Team
June 23, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/PSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As key members of the interdisciplinary care team, thoracic surgeons play an essential role in collaborating and coordinating with their colleagues from other specialties to assess and manage patients with esophageal/GEJ cancer and determine the most appropriate treatment plans based on new evidence inclusive of local and systemic treatment modalities. Thoracic...
Lesley Camille Ballance, MSN, FNP-BC / Amy Goodrich, CRNP / Jill Lozensky, RN, BSN, OCN - Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy
June 22, 2021 23:00 - 56 minutes VideoGo online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of ...
Elizabeth A. Raetz, MD / Rachel Rau, MD - Meeting Therapeutic Challenges in Pediatric ALL: Expert Perspectives on the Use of Asparaginase Compounds
June 22, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ZBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert faculty panel focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric acute lymphoblastic leukemia (ALL) therapy by pairing a sample case scenario with a short lecture designed to illustrate the tactics and techniques for addressing hypersensitivity and effectively utilizing available asp...
Brendon M. Stiles, MD - Immunotherapy as a Game-Changer in Multimodal Management of Locally Advanced and Earlier Stages of Lung Cancer
June 22, 2021 23:00 - 1 hour VideoGo online to PeerView.com/NZQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy currently has a role as consolidation therapy after chemoradiation for patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). Other agents and strategies are being explored in the locally advanced setting as well. Many clinical trials are also investigating the use of immune checkpoint inh...
Suresh S. Ramalingam, MD, FACP, FASCO / Arjun Balar, MD / Yelena Janjigian, MD - Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
June 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/CYY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies have transformed the treatment of many tumors. With the remarkable expansion of checkpoint inhibitors and combinations across the cancer spectrum, reliable predictive biomarkers are essential to guide clinical decisions about treatment selection. PD-L1 expression is the most established immunotherapy biomarker, and several others are in c...
Matthew D. Galsky, MD - The Therapeutic Transformation of Bladder Cancer: Understanding Immune-, Targeted-, and Antibody-Based Models for Patient Care
June 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/EQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in genitourinary malignancies discusses novel therapies for bladder cancer. Upon completion of this activity, participants should be better able to: Cite the regulatory status and treatment roles of novel therapeutic classes in the management of urothelial cancer, Summarize updated evidence on the use of novel therapies, including im...
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
June 18, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, ph...
Amy Goodrich, CRNP - Making Modern Treatment Choices in CLL: Oncology Nurse Insights on the Patient Journey and the New Era of Care
June 18, 2021 23:00 - 1 hour VideoGo online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nu...
Bradley J. Monk, MD, FACS, FACOG / Angeles Alvarez Secord, MD, MHSc - Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice
June 18, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/CHG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For clinicians managing patients with advanced ovarian cancer, the use of poly (ADP-ribose) polymerase (PARP) inhibitors and new treatment modalities such as tumor treating fields (TTFields) represents an important opportunity to provide personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line mainte...
Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment
June 16, 2021 23:00 - 23 minutes VideoGo online to PeerView.com/WNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML. Upon completion of this accredited CE activity, participants should be better able to: Identify the diagn...
"Joseph D. Khoury, MD, FCAP - Visualizing Progress for TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles and Modern Treatment"
June 16, 2021 23:00 - 23 minutes VideoGo online to PeerView.com/WNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML. Upon completion of this accredited CE activity, participants should be better able to: Identify the diagn...
"Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO
June 15, 2021 23:00 - 1 hour VideoGo online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as...
Susana Banerjee, MBBS, MA, FRCP, PhD / William J. Gradishar, MD, FASCO, FACP / Maha Hussain, MD, FACP, FASCO
June 15, 2021 23:00 - 1 hour VideoGo online to PeerView.com/VHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of improved understanding of the genetic mechanisms underlying solid tumors, PARP inhibitors are now validated treatments for patients with ovarian, prostate, breast, and pancreatic cancers. Targeting DNA damage response (DDR) mutations, which have an important role in tumorigenesis, PARP inhibitors are now being studied in other cancers, as well as...
Kurt A. Schalper, MD, PhD / Shanu Modi, MD - HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
June 11, 2021 23:00 - 51 minutes VideoGo online to PeerView.com/FFU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern precision oncology practice relies on detecting molecular alterations that drive specific cancers to target them with matched therapies that yield the best possible outcomes for patients. HER2 alterations are key therapeutic targets in breast cancer, as well as in gastric, colorectal, and non–small cell lung cancers, among other solid tumors. In addition...
Matthew S. Johnson, MD, FSIR / Richard S. Finn, MD - At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC
June 11, 2021 23:00 - 41 minutes VideoGo online to PeerView.com/DCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With several available treatment modalities, hepatocellular carcinoma (HCC) requires a multidisciplinary approach that is based on disease stage and patient factors. The role of the interventional radiologist, always vital in managing intermediate-stage disease via locoregional approaches, has become increasingly more important in the treatment of advanced-stag...
Michael R. Bishop, MD - Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers
June 04, 2021 23:00 - 58 minutes VideoGo online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practice...
Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC
June 01, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ...
Naval Daver, MD - Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights From a Center of Excellence
May 28, 2021 23:00 - 54 minutes VideoGo online to PeerView.com/BFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anders...
Jennifer Wargo, MD, MMSc - The Path Forward for Immunotherapy in Resectable Melanoma: Principles and Perspectives on Using Immune-Based Adjuvant and Neoadjuvant Therapy
May 26, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KNX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading melanoma experts discuss the role of immunotherapy as a standard adjuvant option in stage III/IV—and potentially stage II—disease and the potential of neoadjuvant checkpoint blockade in certain resectable settings (eg, macroscopic stage III disease). Real-world examples of immunotherapy treatment in resectable disease and the foundatio...
Brian I. Rini, MD, FASCO - Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival
May 24, 2021 23:00 - 54 minutes VideoGo online to PeerView.com/BZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in renal cell carcinoma discusses the latest efficacy and safety data on new treatment approaches, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches; applying new clinical trial evidence to the selection and sequencing of combination therapies; and mitigating and managing adverse eve...
Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD / Jonathan A. Nowak, MD, PhD - The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes
May 20, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ZEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies and immunotherapy-based combinations have become key components in the cancer treatment arsenal, and testing for predictive biomarkers to refine patient selection is of increasing importance. Assessment of PD-L1 expression plays an essential role in a number of tumor types, determination of MSI/MMR and TMB status has a place in current pr...
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science
May 17, 2021 23:00 - 33 minutes VideoGo online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss k...
John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
May 14, 2021 23:00 - 35 minutes VideoGo online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts al...
Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs
May 10, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/URQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs). Upon completion of this activity, participants will be able to: Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE, As...
Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer
April 30, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based...
Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses
April 30, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool...
John J. Russell, MD - Rewriting the Rules for Early Cancer Screening: Case-Based Insight on Primary Care Principles for Using Blood-Based Screening Techniques
April 30, 2021 23:00 - 37 minutes VideoGo online to PeerView.com/KXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, experts in oncology and primary care examine how to best integrate future blood-based cancer screening tools into clinical practice in order to reduce cancer-related morbidity and mortality. Upon completion of this activity, participants should be better able to: Explain the scientific principles behind cfDNA-based liquid biopsy as ...
Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies
April 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as we...
Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum
April 13, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe ...
"Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics"
April 08, 2021 23:00 - 53 minutes VideoGo online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should i...
Corey Cutler, MD, MPH, FRCP(C) & Miguel-Angel Perales, MD - New Perspectives in Acute and Chronic GVHD: Challenges and Opportunities for Improving Prophylaxis and Treatment With Novel Therapeutics
April 08, 2021 23:00 - 53 minutes VideoGo online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should i...
Robert Dreicer, MD, MS, MACP, FASCO - Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum
April 02, 2021 23:00 - 1 hour VideoGo online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patie...
Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT
March 31, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completio...
Ruben A. Mesa, MD, FACP / Jeanne M. Palmer, MD - How to Manage JAK Inhibition in Patients Undergoing HCT: Applying the Latest Clinical Evidence to Improve Patient Outcomes in Myelofibrosis
March 26, 2021 23:00 - 58 minutes VideoGo online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decis...
Jason J. Luke, MD, FACP - Expanding the Benefits of Immuno-Oncology to More Patients With Solid Tumors Through Novel Rational Targets and Combinations
March 22, 2021 23:00 - 39 minutes VideoGo online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical ...
Richard S. Finn, MD - How I Think, How I Treat: Remodeling the HCC Treatment Algorithm With New and Emerging Monotherapy, Combination, and Multimodal Approaches
March 17, 2021 23:00 - 34 minutes VideoGo online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint i...
Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes
March 10, 2021 23:00 - 1 hour VideoGo online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts...
Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT
March 08, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovativ...
Milind Javle, MD - A New Dawn in the Therapeutic Management of Biliary Cancers: Integrating Precision Medicine With New and Emerging Targeted Strategies
March 05, 2021 23:00 - 22 minutes VideoGo online to PeerView.com/XXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a biliary cancer expert discusses the latest data on targeted treatments for biliary cancers and gives guidance on integrating precision medicine with new and emerging strategies. Upon completion of this activity, participants should be better able to: Describe the scientific rationale for therapeutic targeting in biliary cancers, including me...
Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies
March 01, 2021 23:00 - 1 hour VideoGo online to PeerView.com/PXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational ...
Manish A. Shah, MD, FASCO - Checkpoint Inhibition in Gastrointestinal Cancers: Recent Advances in Gastric, Esophageal, and Colorectal Cancers and Their Application in Clinical Practice
February 26, 2021 23:00 - 1 hour VideoGo online to PeerView.com/UFG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of ...